Soluble Advanced Glycation End Product (sRAGE) Levels
Completed
- Conditions
- Obese Patients
- Registration Number
- NCT06771986
- Lead Sponsor
- Kayseri City Hospital
- Brief Summary
The aim of this study is to evaluate sRAGE levels in children with obesity and to determine the relationship between metabolic status and sRAGE levels in childhood obesity
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 88
Inclusion Criteria
Clinical diagnosis of Obesity BMI over 95th percentile BMI z-score over 2
Exclusion Criteria
Primary hyperlipidemia Primary liver disease Hypothyroidism Diabetes
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of sRAGE levels in obese and healthy participants From enrollment to the end of at 6 months
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does sRAGE correlate with insulin resistance markers in childhood obesity?
What metabolic biomarkers predict sRAGE elevation in pediatric obesity populations?
Can sRAGE levels stratify cardiovascular risk in obese children compared to standard lipid panels?
What molecular pathways link sRAGE to adipokine dysregulation in pediatric metabolic syndrome?
How do sRAGE concentrations compare between NAFLD and non-NAFLD obese children?
Trial Locations
- Locations (1)
Kayseri City Hospital
🇹🇷Kayseri, Turkey